Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Xolair price per dose?

See the DrugPatentWatch profile for Xolair

Prices for Xolair (omalizumab) vary a lot by country, dose, and vial size, plus whether you have insurance or manufacturer programs. Here’s a rough guide:

- United States (list price, approximate):
- A single 150 mg vial costs about $1,000–$1,600.
- Doses often require 1–4 vials (150 mg each) depending on body weight and IgE level (common ranges are 150–600 mg per dose).
- Therefore, per-dose cost can be roughly $1,000–$6,000 or more.

- Example calculations (illustrative):
- 150 mg dose: 1 vial → about $1,000–$1,600.
- 300 mg dose: 2 vials → about $2,000–$3,200.
- 450 mg dose: 3 vials → about $3,000–$4,800.
- 600 mg dose: 4 vials → about $4,000–$6,400.

- Other countries: typically lower after negotiations and subsidies, but exact prices vary by country and payer.

Important caveats:
- These are list prices. Actual costs to patients can be lower or higher depending on insurance coverage, copays, manufacturer assistance programs, and local pricing.
- Administration/injection visit fees and any required monitoring may add to the total cost.

If you tell me your country, typical dosing (mg per dose and how often you’d get a dose), and whether you have insurance or a patient-assistance program, I can give a more tailored estimate.



Other Questions About Xolair :

Xolair biosimilar? Xolair approval date? How much does xolair cost without insurance? Xolair route of administration? Xolair patent expiration? Xolair strengths? When xolair patent expire?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response’s claim that XOLAIR has a WARNING for anaphylaxis is directly supported by the provided FDA label text (Boxed Warning and Warnings/Precautions sections), including characteristic symptoms and monitoring/management instructions.


Category Scores

Warnings
100
Excellent

Accurate Statements

XOLAIR includes a Boxed Warning for anaphylaxis, described as a reported risk after administration with characteristic signs/symptoms and instructions to initiate in a healthcare setting and observe patients.
BOXED WARNING (Box) and Warnings and Precautions (5.1) provided in the prompt (initiate in healthcare setting; closely observe; symptoms including bronchospasm, hypotension, syncope, urticaria, and/or angioedema of throat or tongue).
The label further elaborates on anaphylaxis in Warnings and Precautions (5.1) and provides additional postmarketing safety details (6.2).
5.1 (Anaphylaxis) and 6.2 (Postmarketing Experience) provided in the prompt.

Unsupported Statements


Contradictions


Important Omissions

The response does not explicitly mention the label’s limitation-of-use statements indicating XOLAIR is not indicated for emergency treatment of allergic reactions/anaphylaxis (Sections 1.3 and 5.9).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated claim is accurate and label-consistent regarding the presence of anaphylaxis warning/boxed warning; no contradictory safety assertions were made.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omission of the label’s explicit limitations-of-use stating XOLAIR is not indicated for emergency treatment of allergic reactions/anaphylaxis.

Suggested Improvement
When discussing anaphylaxis warnings, also note the label’s limitation-of-use/emergency treatment cautions from Sections 1.3 and 5.9.